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Fluorescence lifetime imaging microscopy (FLIM) and single-molecule super-resolution microscopy (SRM) illustrate the
intracellular fate of Sn-2 phosphatidylcholine prodrugs.

Abstract
While the in vivo efficacy of Sn-2 phosphatidylcholine prodrugs incorporated into targeted, nonpegylated lipid-encapsulated nanoparticles was demonstrated in prior preclinical studies, the
microscopic details of cell prodrug internalization and trafficking events are unknown. Classic
fluorescence microscopy, fluorescence lifetime imaging microscopy, and single-molecule superresolution microscopy were used to investigate the cellular handling of doxorubicin-prodrug and
AlexaFluorÔ-488-prodrug. Sn-2 phosphatidylcholine prodrugs delivered by hemifusion of
nanoparticle and cell phospholipid membranes functioned as phosphatidylcholine mimics,
circumventing the challenges of endosome sequestration and release. Phosphatidylcholine prodrugs in
the outer cell membrane leaflet translocated to the inner membrane leaflet by ATP-dependent and ATPindependent mechanisms and distributed broadly within the cytosolic membranes over the next 12 h.
A portion of the phosphatidylcholine prodrug populated vesicle membranes trafficked to the perinuclear
Golgi/ER region, where the drug was enzymatically liberated and activated. Native doxorubicin entered
the cells, passed rapidly to the nucleus, and bound to dsDNA, whereas DOX was first enzymatically
liberated from DOX-prodrug within the cytosol, particularly in the perinuclear region, before binding
nuclear dsDNA. Much of DOX-prodrug was initially retained within intracellular membranes. In vitro
anti-proliferation effectiveness of the two drug delivery approaches was equivalent at 48 h, suggesting
that residual intracellular DOX-prodrug may constitute a slow-release drug reservoir that enhances
effectiveness. We have demonstrated that Sn-2 phosphatidylcholine prodrugs function as
phosphatidylcholine mimics following reported pathways of phosphatidylcholine distribution and
metabolism. Drug complexed to the Sn-2 fatty acid is enzymatically liberated and reactivated over many
hours, which may enhance efficacy over time.
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AF488
API
αvβ3
CFDD
cPLA2
DAPI
DMEM
dsDNA
ER
FLIM
MC540
PAINT
Paz-PC
PC
PD
PFOB
PE
PE-PTX
PLA
SRM
Sn-2
τamp

AlexaFluorÔ 488
active pharmaceutical ingredient
alpha v beta 3 integrin
Contact Facilitated Drug Delivery
cytosolic phospholipase A2
4',6-Diamidino-2-phenylindole, dihydrochloride
Dulbecco's Modified Eagle’s Medium
double-stranded deoxyribonucleic acid
endoplasmic reticulum
fluorescence lifetime imaging microscopy
merocyanine 540
Point Accumulation for Imaging in Nanoscale Topography
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine"
phosphatidylcholine
prodrug
perfluoro-1-bromooctane
phosphatidylethanolamine
phosphatidylethanolamine-paclitaxel
phospholipase
super-resolution microscopy
stereospecific numbering position 2
amplitude average lifetime
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constituents. The very poor particle retention of
these drugs accounted for their lack of efficacy
in cancer models when studied in vivo [10].
In an earlier report, rhodamine-PE was
employed as a fluorescent drug surrogate to
illustrate and elucidate the CFDD mechanism.
Rhodamine-PE delivered with integrin-targeted
PFC NP integrated into the cell membrane upon
binding and readily passed via lipid rafts into C32 human melanoma cells at 37°C [4]. In
contradistinction to rhodamine-PE, paclitaxel
conjugated to phosphatidylethanolamine failed
to translocate from the outer to inner cell
membrane leaflets. The concept of chemically
coupling drugs to the Sn-2 fatty acid of
phosphatidylcholine (PC) was envisioned as an
alternative approach to facilitate nanoparticle
drug retention during circulation, to protect
chemically-sensitive
compounds
from
interactions with blood constituents, and to
transfer into the targeted cell via CFDD. In vivo
studies demonstrated that the Sn-2 prodrug
motif was efficacious for fumagillin, docetaxel,
and recently cMYC-inhibitors [9-12].
While the concept of Sn-2 phospholipid
prodrugs was never considered for ligandtargeted drug delivery in association with the
CFDD hemifusion mechanism, precedence for
Sn-2 phospholipid prodrugs was found to exist,
initially reported by David Thompson et al. in
the context of triggered drug release
mechanisms [13].
Later, Andresen and
colleagues [14-24] pursued an approach to
deliver chemotherapeutics as Sn-2 prodrugs via
untargeted liposomes, anticipating that
phospholipases liberated locally by cancers
would trigger local drug release.
Their
hypothesis was essentially incorrect. Physicalchemical modeling by this team revealed that
non-pegylated liposomes were resistant to free
water penetration and premature hydrolysis of
the synthetic ether-lipid prodrugs. However,
pegylation of liposomes, a design feature
commonly employed to extend circulatory halflife, wicked water into the membrane creating
access to lipases with resultant rapid premature
drug release.
Phosphatidylcholine (PC) populates all cell
and intracellular membranes in contrast to
phosphatidylethanolamine
or
phosphatidylserine, which preferentially reside
in the inner cell membrane leaflet and other
specific organelles, such as the mitochondria
[25, 26]. The Sn-2 PC prodrug motif was

Rationale and purpose
Sn-2 phosphatidylcholine prodrugs in nonpegylated lipid nanoparticle membranes are
known to be resistant to premature release and
metabolism in circulation. This approach using
targeted drug delivery has been demonstrated to
be effective in a variety of preclinical models.
Cellular uptake of these compounds is
hypothesized to be secondary to a hemifusion
contact-facilitated drug delivery mechanism
with cytosolic enzymatic drug release, which
circumvents sequestration in the endosomelysosome pathway. This research utilized
advanced complementary optical imaging
methods, including confocal fluorescence
lifetime and super-resolution single molecule
microscopy, to elucidate and compare PC
prodrug cellular trafficking and metabolism
with previously known paths of natural PC.

Introduction
The concept of achieving Paul Erhlich’s
inspired vision of a “magic bullet” to treat
disease remains challenging in the context of
nanomedicine. While specific reasons vary
among nanosystems, in general, early systemic
drug loss, low net drug delivery to targeted
cells, and limited free drug intracellular
bioavailability have been major barriers [1].
Very hydrophobic drugs, such as fumagillin,
incorporated into the phosphatidylcholinebased surfactant membranes of αvβ3-targeted
nanosized emulsion particles [2-7] provided
anti-angiogenic benefits that were broadly
demonstrated in vitro and in vivo by imaging,
microscopy, and functional outcomes [3, 6-8].
Hydrophobic drugs dissolved into the lipid
surfactant spontaneously transferred to targeted
cell membranes through an irreversible
hemifusion process referred to as contactfacilitated drug delivery (CFDD) [2, 4]. Despite
in vivo effectiveness, the pharmacokinetics of
the drug relative to the other lipid surfactant
components and the perfluorocarbon (PFC)
core were discrepant and showed marked
premature fumagillin loss during circulation
[9]. Lipid-anchored homing ligands and
gadolinium chelates co-incorporated into the
surfactant of PFC nanoparticles (NP) had
similar pharmacokinetic clearance rates as a
percentage of injected dose in rodents. Less
hydrophobic drugs dissolved into the lipid
surfactant, such as paclitaxel or doxorubicin,
had rapid circulatory clearance rates compared
to the PFC NP core and other membrane
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adopted as a PC mimic that would circumvent
endosomal NP internalization and resultant
losses by intercalation into the cell membrane
and trafficking throughout the intracellular
membranes until lipases, such as phospholipase
A2, liberated a bioactive drug. However, this
working hypothesis for the effectiveness of Sn2 PC prodrug has never been elucidated.
In the present study, complementary
microscopic imaging techniques were utilized
to explore cell membrane uptake, cellular
internalization and intracellular distribution of
a doxorubicin Sn-2 PC prodrug or
AlexaFluor™ Sn-2 PC prodrug. The objectives
were to compare the biopotency of a
phosphatidylcholine doxorubicin prodrug
(DOX-PD) with free doxorubicin (DOX) and to
utilize
fluorescence
lifetime
imaging
microscopy (FLIM) to compare the trafficking
of DOX-PD versus free DOX from the outer
cell membrane to the nucleus. To corroborate
and extend the FLIM results, single-molecule
super-resolution optical microscopy [27-29]
was employed to map Sn-2 AlexaFluorÔ 488
prodrug (AF488-PD) trajectories from the cell
membrane uptake, outer to inner membrane
leaflet transfer, and throughout the intracellular
membranes.

discrimination between drug retained in cell
membranes, enzymatically released into the
cytosol, or in the nucleus bound to dsDNA.
Super-resolution
optical
microscopy
dynamically tracked single prodrug (AF488PD) molecules across multiple focal planes,
demonstrating spatial uptake, translocation and
distribution within the cell until the dye was
enzymatically liberated, after which rapid
molecular motion beyond the confocal volume
precluded detection. Collectively, these
observations and measurements demonstrate
the CFDD drug delivery mechanism of PC
prodrugs and the avoidance of endosomal
sequestration and degradation.

Materials and methods
Synthesis and characterization of
doxorubicin and AlexaFluorÔ 488
prodrugs
Doxorubicin Sn-2 prodrug conjugates
(DOX-PD) were synthesized in our laboratory
starting
from
commercially
available
doxorubicin (Sigma Aldrich, St. Louis, MO)
and oxidized phospholipids (NOF America,
White Plains, NY).
In this approach,
doxorubicin (0.22 mM) was dissolved in
dimethylsulfoxide (DMSO) and triethylamine
(1 mM). Added to this solution was (S)-2-(8carboxyoctanoyloxy)-3-(palmitoyloxy)propyl
2-(trimethylammonio)
ethyl
phosphate
(PAzPC, 0.2 mM, NOF America) dissolved in
chloroform with cyclohexylcarbodiimide (1
mM).
The reagent mixture was shaken
overnight at room temperature (RT) then
purified
using
silica
gel
column
chromatography. The desired product DOX-PD
was characterized using mass spectroscopy:
Chemical Formula: C60H91N2O20P, ESI-MS
M+H+ Cal. 1190.63, exp.1191.6 (Shimadzu
LCMS 2010A, Kyoto, Japan) (Figure S1).
The
AlexaFluorÔ
488
Sn-2
phospholipid conjugate (AF488-PD) was
synthesized from commercially available
AlexaFluorÔ 488 (Thermo Fisher Scientific,
Waltham,
MA)
and
oxidized
phosphatidylcholine (NOF America, PAzPC).
In this approach, AlexaFluorÔ 488 cadaverine
(1.56 µmoles in 1 mL dimethylformamide) was
combined with excess PAzPC (6.6 µmole)
dissolved in 2 mL chloroform to which
triethylamine
(50
µl)
and
N,N’diisopropylcarbodiimide (50 µL) were added.
The mixture was reacted for 2-3 hours.

Experimental design
The present study employed traditional
fluorescence
microscopy,
confocal
fluorescence lifetime imaging microscopy
(FLIM), and single molecule super-resolution
optical microscopy in a complementary fashion
to
track
optically
active
Sn-2
phosphatidylcholine prodrug in normal and
cancerous cells. The experimental protocols
utilized a doxorubicin prodrug for fluorescence
microscopy and confocal fluorescence lifetime
imaging for assessments of the cell membrane,
cytosol, and nucleus. A more photostable dye,
AlexaFluor™ 488, was synthesized into an Sn2 prodrug motif to detect single prodrug
molecules in the presence of autofluorescence.
This enhanced photostability extended the
SRM tracking time and permitted better
estimates of molecular migration patterns and
prodrug membrane retention.
Fluorescence microscopy differentiated free
DOX and DOX-PD distribution from the outer
cell membrane, cytoplasm and nucleus. FLIM,
which assessed distributions between local
biochemical environments based on changes in
excited-state lifetimes, offered qualitative
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Separation
with
silica
TLC
(0.2M
NH4Ac:MeOH:water - 20:100:200) revealed
only the conjugated dye (RF 0); the free dye
control was seen at RF ~ 0.8. The sample was
dialyzed (MWCO 500-1000) then lyophilized.
Purified AF488-PD was characterized using
mass spectroscopy: final chemical formula was
C74H113N7NaO23PS2+2H+, ESI-MS M+H+ Cal.
793, exp.793.85 (Shimadzu LCMS 2010A,
Kyoto, Japan) (Figure S1).

Cell culture
For fluorescence microscopy, 2F2B mouse
endothelial cells (ATCC CRL2168, Manassas,
VA, USA) were cultured in Dulbecco's
modified Eagle's medium (DMEM, no phenol
red, Gibco, Thermo Fisher Scientific, Waltham,
MA) with 4.5 g/L glucose and 10% heat
inactivated fetal bovine serum. Cells were
plated on sterile 12 mm cover glasses (#1.5) in
a 24 well plate at approximately 1x105 cells per
well and incubated overnight at 37 °C in a 5%
CO2 incubator. Doxorubicin (Sigma, St Louis,
MO, USA) or αvβ3-DOX-PD PFOB NPs were
added to the cells at a final concentration of 3
µM active drug in complete media. After 1 h,
the cells were washed three times in PBS and
fixed in 4% paraformaldehyde solution for 30
min. The coverslips were rinsed in PBS; the
cell nuclei were stained blue with DAPI (4',6diamidino-2-phenylindole, dihydrochloride);
and samples were analyzed by fluorescence
microscopy (Olympus BX61, Shinjuku, Tokyo,
Japan).
For confocal fluorescence lifetime imaging
microscopy, human C-32 melanoma cells
(Washington University Tissue Culture
Support Center, St. Louis, MO) were cultured
in Minimal Essential Media containing Earle’s
salts (no phenol red, Gibco, Thermo Fisher
Scientific, Waltham, MA) and supplemented
with 10% (v/v) fetal bovine serum (SigmaAldrich, St. Louis, MO), 1% penicillin and 1%
streptomycin (Gibco).
The cells were
trypsinized and plated on glass bottom dishes
(35 mm, glass #1, MatTek Corporation,
Ashland, MA) and grown overnight in phenol
red-free media. The drug formulations were
diluted in the culture media and cells were
incubated for varying times. After incubation
and washing, fluorescence lifetime imaging
was performed on live cells in a humidified
stage-top incubator with 5% CO2.
For super-resolution imaging, 2F2B mouse
endothelial cells were cultured in DMEM with
10% fetal bovine serum (Gibco) plus 1%
penicillin and 1% streptomycin (Gibco) and
incubated at 37ºC with 5% CO2. 2F2B cells
were trypsinized and plated on ozonepretreated high-tolerance coverslips (No. 1.5,
170 ± 5 μm thickness, Azer Scientific,
Morgantown, PA), and incubated for 48 h. The
cells were further treated with 1.6 μg/mL
AF488-PD at 37 ºC for 12 h, or 0.05 μg/mL
AF488-PD at room temperature for 5 min

Synthesis and characterization of αvβ3
DOX-PD PFOB nanoparticles
Nanoparticles (NP) were prepared as a
microfluidized suspension of 20% (v/v)
perfluoro-1-bromooctane (PFOB, Exfluor
Research Corporation, TX), 2.0% (w/v) of a
surfactant co-mixture and 1.7% (w/v) glycerin
in Milli-Q® water. An αvβ3-integrin antagonist,
a quinolone nonpeptide developed by BristolMyers Squibb Medical Imaging (US patent US
6511648 and related patents) was used for
homing (a gift, Kereos, Inc., St. Louis, MO).
The
surfactant
co-mixture
included:
approximately 97.6 mole% lecithin, 0.15
mole% of αvβ3-ligand-conjugated lipid and 2.28
mole% of DOX-PD (0.5 mM). The surfactant
components were combined with the PFOB,
buffer and glycerine and Milli-Q® water, then
the mixture was homogenized at 20000 psi for
4 min. The NP were preserved under inert gas
in sterile sealed vials until use. Nominal αvβ3DOX-PD PFOB NP and size by dynamic light
scattering was 260 nm, with a polydispersity of
0.14 and zeta potential of -7.4 mV. The
surfactants of fluorescent PFOB NP
incorporated
0.1
mol%
rhodaminephosphatidylethanolamine
(Avanti
Polar
Lipids, Alabaster, AL) or 0.1 mol% AF488-PD
in the lipid commixture at the expense of
phosphatidylcholine.

Absorption and fluorescence
spectroscopy
DOX and DOX-PD were used for absorption
and fluorescence spectroscopy. The materials
were diluted in Milli-Q® water. Absorption
spectra were measured on a DU 640
spectrophotometer (Beckman-Coulter, Brea,
CA). Fluorescence emission spectra were
recorded on a FluoroLog 3 spectrofluorometer
(Horiba Jobin Yvon, Edison, NJ) using 585
nm/600-700 nm as excitation/emission
wavelength with 5 nm slits.
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234

before imaging. The 2F2B cells were also
treated with 1.4 μM PE-rhodamine at 37 ºC for
1 h and rinsed with PBS for standard
epifluorescence imaging.

𝑦(𝑡) = ' 𝐴[𝑖]exp {−
567

Cytotoxicity assay

Equation 1
Where: n = number of exponentials (n ≤ 2 for
all cases depending on goodness of fit); A =
amplitudes; 𝜏 = lifetimes; Bkgr = correction for
background
(after-pulsing,
dark
counts,
environmental light).
Spectroscopy data were fit to mono- or biexponential decay fits (depending on goodness
of fit). For cell images, raw decay data from all
cellular pixels were fit to bi-exponential models
and this method was used to generate the
corresponding lifetime images.
For cell compartment specific analyses,
nuclear, perinuclear and extra-perinuclear
regions of interest (ROIs) were drawn to
achieve 1000 or more counts to ensure effective
bi-exponential decay analysis. Bi-exponential
tail fit was used to fit decays from each ROI and
individual components (lifetime and amplitude)
were obtained. Good χ2 values (0.8-1.2) and
random distribution of x-axis residuals were
considered necessary for an accurate decay fit.
Amplitude average fluorescence lifetimes (τamp)
were calculated and reported using the
following model and reported as average
lifetime values.

The retained cytotoxicity of DOX-PD
was compared to native DOX in mouse
endothelial cells. 2F2B cells were seeded on a
96 well plate (2000-5000 cells/well) in DMEM
with 10% heat-inactivated fetal bovine serum
plus 10 µM angiotensin II (Sigma-Aldrich, St.
Louis, MO) then incubated at 37 ºC with 5%
CO2. After 24 h, cells were incubated for 1 h
with a) αvβ3-DOX-PD PFOB NP (0.3 µM DOX
PD), b) equimolar equivalent of native
doxorubicin HCl or c) αvβ3-No drug NP. After
incubation the wells were washed three times
with PBS and returned to the incubator for 48
h. Cell proliferation was measured using the
MTT assay for cytotoxicity, which measures
the activity of cellular enzymes that reduce the
tetrazolium dye to the insoluble formazan
(Invitrogen;
Thermo-Fisher
Scientific,
Waltham, MA). Each treatment was replicated
6 times.

Fluorescence lifetime spectroscopy,
imaging and data analysis
Confocal fluorescence lifetime spectroscopy
and imaging was performed with a MicroTime
200 microscope (Picoquant, Berlin, Germany).
For spectroscopy, fluorescence lifetimes of
DOX (50 µM) and DOX-PD (50 µM) solutions
in MilliQ® water (final DMSO 0.5%) were
measured under a 100X oil immersion
objective with 485 nm (15 au) laser excitation
pulsed at 40 MHz. Decay data were collected
through a 519 nm long pass filter and
accumulated until peak photon counts reached
10,000. Almost identical conditions were
applied for αvβ3-DOX-PD PFOB NPs (25 µM
doxorubicin concentration) except the pulse
rate was reduced to 20 MHz in order to capture
its slower decay. Live cell imaging utilized 485
nm laser excitation (~1000 au) at 20 MHz on
cells maintained in a stage top CO2 incubator
for the period of imaging.
Lifetime decay data collected from
spectroscopy and microscopic imaging were
analyzed on the SymphoTime software
(Picoquant, Berlin, Germany). All decays were
fit using multi-exponential tail fit using the
equation below:
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A67

Equation 2
Analyzed data was plotted using Prism
(Graphpad, La Jolla, CA). Wherever required,
appropriate statistical analysis was performed
using Prism’s built-in functions and
corresponding p values were reported.

Super-resolution imaging and data
analysis
Single-molecule super-resolution imaging
was used to image the binding and cellular
uptake of individual prodrug molecules. First,
images of individual fluorescent molecules
with switchable bright-dark states (blinking)
were captured, and their positions were
measured by fitting each blinking event to a
two-dimensional Gaussian function. A superresolved image was then reconstructed by
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combining all positions from the stochastic
blinking events of fluorescent molecules. To
resolve the fluorescence signal from a single
molecule, a bright fluorophore, AlexaFluorÔ
488 (AF488), was used and conjugated to the
phospholipid at the Sn-2 position as the prodrug
analog for super-resolution imaging. AF488PD was more photostable than DOX-PD and
permitted detection of single copies of AF488PD in the presence of autofluorescence,
extending SRM tracking time and improving
estimates of molecular migration patterns and
prodrug membrane retention. Freely-diffusing
AF488-PD in the extracellular buffer and in the
cytosol were not captured, since their quicklymoving fluorescence signals were out of focus
and/or averaged out by the detector. However,
when AF488-PD temporarily docked onto the
lipid membrane, its slowed diffusion was
captured and localized from which a superresolution image was reconstructed with spatial
resolution beyond refraction limit. In this way,
single-molecule super-resolution imaging
precisely localized the prodrug molecules with
single-molecule sensitivity.
Super-resolution imaging was performed on a
home-built microscope equipped with a 100X
oil immersion objective (Figure S2) [30, 31].
After AF488-PD incubation, the cells were
washed with PBS to remove the excess prodrug
in the media. Cells were first illuminated with a
488-nm laser (OBIS, Coherent) at a peak
intensity of 0.12 kW⁄cm2 at the sample. The
images were filtered with a 523/610 dual-band
bandpass filter (Semrock FF01-523/610) and
acquired by a sCMOS camera (Hamamatsu,
C11440-22CU) with a 50 ms exposure time.
Next, merocyanine 540 (MC540, Invitrogen)
was introduced to cell media to image the cell
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membranes via PAINT (Point Accumulation
for Imaging in Nanoscale Topography) [32].
Similar to AF488-PD, localizations were only
acquired when MC540 temporarily docked
with the cell membranes and emitted bright
fluorescence, thereby enabling the colocalization of prodrug molecules relative to
cell membrane with nanoscale resolution.
MC540 was excited with a 561-nm laser
(Sapphire, Coherent) at a peak intensity of 2.7
kW⁄cm2 at the sample, and images were
acquired with a 50 ms exposure time. The
single AF488-PD and MC540 molecules were
identified and localized by two-dimensional
Gaussian fitting using an ImageJ plug-in
ThunderSTORM [33].
The super-resolution images of prodrug and
cell membranes consist of the sum of all
localizations from AF488-PD and MC540
respectively, binned as a 2D histogram with bin
size 58.5×58.5 nm2. AF488-PD localizations
over time were grouped into a trajectory when
present in consecutive frames (up to a 3-frame
gap) within a distance of 0.59 μm. The
trajectories were plotted using custom software
(MATLAB, MathWorks). No trajectory
analysis was performed for the endothelial
filopodia.

Results
Spectroscopic characterization of
synthesized prodrugs
Absorption and fluorescence spectra and
decay characteristics of the materials were
measured in a water solution. DOX and DOXPD had similar absorption spectra (Figure 1A).
The spectra for αvβ3-DOX-PD PFOB NP was
obscured by light scattering.
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Figure 1. Spectroscopic characterization of doxorubicin (DOX), doxorubicin prodrug (DOX PD), and αvβ3-integrin
targeted prodrug nanoparticles (αvβ3-DOX-PD PFOB-NPs) in water: Absorption spectra of the materials (A). The absorption
of doxorubicin prodrug in nanoparticle formulation is obscured by light scattering. Presence of doxorubicin is confirmed in
the corresponding fluorescence emission (B). Fluorescence decay characteristics of the materials (C). DOX decay can fit to
mono-exponential decay of 1.09 ± 0.02 ns. DOX-PD can fit to bi-exponential decay with τa = 1.21 ns (47%); τb = 0.69 ns
(53%). DOX-PD NP can fit to bi-exponential decay with τa = 3.78 ns (22%); τb = 1.34 ns (78%). Data represent mean ± sd,
n=3 measurements. IRF – Instrument response function.

All drug formulations showed similar
fluorescence
emission
spectra,
which
corroborated the presence of doxorubicin in the
nanoparticles (Figure 1B). The emission peak at
~556 nm for doxorubicin in the αvβ3-DOX
PFOB NP was relatively more prominent. This
observation may reflect the unique interactions
of the doxorubicin molecules with the core
PFOB molecules that penetrate to the particlewater interface [34].
As shown in Figure 1C, free DOX
fluorescence fit a mono-exponential decay of
1.09 ± 0.02 ns (χ2 = 1.06), consistent with
literature findings. DOX-PD decay best fit a biexponential decay model with nearly equal
contributions from a fast lifetime component τa
= 0.69 ± 0.06 ns (53%) and a slow lifetime
component of τb = 1.21 ± 0.03 ns (47%),
indicative of a heterogeneous system (χ2 =
1.007). The amplitude average lifetime (τamp)
was calculated to be 0.96 ± 0.04 ns. Dynamic
light scattering analysis of a DOX-PD in water
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revealed a mixed suspension of free prodrug
molecules and spontaneously formed prodrug
micelle aggregates (~1600 nm). Fluorescence
lifetime of doxorubicin bound to biological
molecules (lipid membranes, DNA) and while
encapsulated in nanoparticles increases as the
molecules are shielded from external
fluorescence quenchers and by p-p stacking
[35-38]. Hence, the slower lifetime component
from DOX-PD suspension was attributed to the
micellar fraction of the drug distribution where
the anthracycline portion of DOX-PD was
shielded from surrounding water molecules.
The faster lifetime of 0.69 ns can be attributed
to the free DOX-PD molecules in water. This
value is slightly different than that of free DOX
in water, reflecting the effect of drug
conjugation with the lipid molecule.
Fluorescence decay of αvβ3-DOX-PD PFOB
NP fit a double exponential decay model with
components τa = 3.78 ± 0.03 ns (22%) and τb =
1.34 ns (78%) (χ2 = 1.03). The majority of the
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αvβ3-DOX-PD PFOB NP had the faster
fluorescence lifetime component (1.34 ns)
similar to that of DOX-PD in the micellar
fraction (1.21), indicating similar hydrophobic
interactions. The slower lifetime fractional
component (3.78 ns) is likely related to
hydrophobic interactions of DOX-PD within
the nanoparticle lipid surfactant intercalated
between PFOB molecules.

Cellular uptake and cytotoxicity of αvβ3DOX-PD PFOB NP
The cellular distribution of DOX presented as
the free drug and delivered within nanoparticle
surfactant in prodrug form was observed with
fluorescence microscopy (Figure 2).

Figure 2. Cellular internalization and cytotoxic effects of αvβ3-DOX-PD PFOB-NP: Internalization of DOX and αvβ3DOX-PD PFOB-NP in 2F2B cells incubated with reagents for 30 min. Red shows doxorubicin fluorescence signal and blue
is nuclear counterstain, overlay is purple. (A) 2F2B cells treated with free DOX showing most red signal localized into nucleus
(white arrow). (B) 2F2B cells treated with αvβ3-DOX-PD PFOB-NP showing signal diffuse through cytosol, membrane
(yellow arrow) and nucleus (white arrow). (C) MTT cytotoxicity assay after 48 h of treatment, showing αvβ3-DOX-PD PFOBNP was significantly more cytotoxic than the equivalent dose of free DOX (p<0.05) while drug-free NP had no effect on cell
proliferation. Statistical analysis was performed using unpaired Student's T test and p values were assigned.

Benign 2F2B mouse endothelial cells were
exposed to DOX and αvβ3-DOX-PD PFOB NP.
Free DOX internalized and localized rapidly to
cell nuclei within 30 min of treatment with
negligible cytosolic retention noted (Figure
2A). DOX-PD delivered by αvβ3-targeted NP
bound to the cell membrane periphery, entered
the cell via the CFDD mechanism and rapidly
dispersed into the cytosol membranes. Lipasereleased DOX was observed in the nucleus
(Figure 2B). Circumventing cell internalization
with endosome sequestration and escape, a
common pathway for nanoparticle drug
delivery, DOX-PD dispersed throughout the
cytoplasmic
membrane.
Enzymatically
liberated DOX accumulated in the nucleus.
The cytotoxic bioactivity of αvβ3-targeted
DOX-PD PFOB NP referenced to equimolar
free DOX was assessed in 2F2B mouse
endothelial cells stimulated with angiotensin II
using the MTT cytotoxicity assay. The control
αvβ3-no-drug NP had no impact on cell
proliferation (Figure 2C). Both free DOX
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added to the media and αvβ3-DOX-PD PFOB
NP were cytotoxic (Figure 2C). At 48 h αvβ3DOX-PD PFOB NP decreased cell proliferation
by 44% (P<0.01) as compared to the control
αvβ3-no-drug NP. An equivalent dose of free
DOX decreased cell proliferation by 19%
(P<0.05) compared to the control. The αvβ3DOX-PD PFOB NP was significantly more
toxic than equivalent amounts of free DOX
(P<0.05). These data showed that the Sn-2
coupling of DOX to the phosphatidylcholine
lipid backbone did not compromise drug net
bioactivity and suggested that continued
liberation of DOX from the DOX-PD reservoir
retained in the cytoplasm over 48 hours
contributed to effectiveness.

Temperature dependent cellular uptake
of αvβ3-DOX-PD PFOB NP
Fluorescence imaging of prodrug trafficking
performed in normal proliferating endothelial
cells was reflective of previous antiangiogenesis experiments [10, 12, 39, 40] with
Sn-2 prodrugs. As opposed to normal
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proliferating endothelial cells, the next
experiments explored Sn-2 prodrug behavior in
abnormal human C-32 melanoma.

Drug uptake from αvβ3-DOX-PD PFOB NP
was studied in cultured C-32 cells at 37 °C and
at 4 °C, the later to induce cold suppression of
ATP-dependent mechanisms (Figure 3).

Figure 3. Effect of temperature on cellular uptake of αvβ3-DOX-PD PFOB-NP: Comparison of cellular uptake of αvβ3DOX-PD PFOB-NP after 1 h incubation at 37 degrees (A) and 4 degrees C (B). Control untreated cells show near zero signal
(C). Quantified background corrected whole cell fluorescence (mean ± sem, n=5 cells for each of the 3 independent
experiments) showing internalization is reduced at 4 degrees C (D).

DOX-PD transfer from the bound
nanoparticle surfactant to the outer cell
membrane leaflets was similar under both
temperature regimens. While transfer of DOXPD from the outer to inner cell membrane
leaflets was rapid and unimpaired at 37 °C, at 4
°C DOX-PD delivery to the inner leaflet and
contiguous intracellular membranes was
reduced but notably present well-above
background fluorescence. This was in
contradistinction to previous studies using
rhodamine-PE as a drug surrogate in which
translocation of the fluorescent lipid from the
outer to inner cell membrane leaflets was
blocked at 4 °C. These data suggest that DOXPD and other PC-PD will translocate between
membrane leaflets by ATP-dependent and
ATP-independent mechanisms and slowly
diffuse into cells in the absence of energy.
Pixel-by-pixel fit of the raw decay data shows
gradient of amplitude average lifetime τamp
throughout the cells (Figure 4B). Untreated
cells showed minimal background signal under
these imaging conditions (Figure S4). We
performed cell compartment specific analysis
of our lifetime data as below (Figure S5).
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Nucleus
Nuclei of cells treated with DOX and αvβ3DOX-PD PFOB-NPs showed similar lifetime
distribution suggesting that DOX liberated
from lipid prodrug retained the same dsDNA
binding character as the native compound
(Figure S3). Previous studies have reported
DOX bound to dsDNA exhibits higher lifetime
(2.2 ns – 1.3 ns, [37, 38, 41]). Upon fitting
decays from nuclear ROIs using bi-exponential
model, a major component of fast lifetime 1.44
ns ± 0.06 ns (80% ± 4%, n=52) was detected
reflecting dsDNA-bound DOX. A minor slow
lifetime component (3.80 ± 0.24 ns) in the
nucleus was attributed to noise from
backscattering of excitation light and autofluorescence, which was also noted for
untreated cells (Figure S4). τamp in the nuclei
decreased steadily between 1 h (2.11 ± 0.04 ns)
and 8 h (1.82 ± 0.02) post-incubation (Figure
4C, P<0.001). This observation was previously
observed by others and attributed to druginduced apoptosis with consequent remodeling
of chromatin network in the nucleus [41].
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Figure 4. Fluorescence lifetime imaging of C-32 cells treated with αvβ3-DOX-PD PFOB-NP. Fluorescence intensity images
of C-32 cells with αvβ3-DOX-PD PFOB-NP for 1, 4, 8, and 24 h, showing doxorubicin fluorescence from cell cytoplasm and
nucleus at all time points. A perinuclear space with high signal intensity is observed in all cells (red arrows) indicating
accumulation of drug (A). Corresponding fluorescence lifetime images generated by pixel-by-pixel fitting of decay data show
a gradient of τamp in different cell compartments (B). Quantification of τamp from nuclear compartments shows time dependent
decrease (n= 7-18 cell nuclei at each time point, 3 independent experiments, p<0.001) suggested drug induced apoptosis (C).
Percentage contributions of slow and fast components in the bright perinuclear region (τamp = 1.8 ± 0.2 ns) compared to the
rest of the cytosol ((τamp = 2.9 ± 0.3 ns)) for cells treated with αvβ3-DOX-PD PFOB-NP for 8 h (D). Bright perinuclear ROIs
show greater contribution of fast lifetime than cytosolic regions outside it (mean ± sem, n= 15 cell ROI measurements).
Statistical analysis was performed using unpaired Student's T test and statistical significance was assigned for p<0.001,
represented by ***.

suggesting an abundance of free DOX
molecules. In the surrounding cytosol, this
faster component was much less in proportion
(1.06 ns, 52% ± 8%), indicating lower amounts
of free DOX (Figure 4D). The slower lifetime
components from both perinuclear and
surrounding regions was attributed to a
combination of background (as observed in cell
nuclei) and from bound drug (as observed in
literature and our spectroscopic studies). By
extension, the collective data suggested that
phospholipase
release
of
Sn-2-linked
doxorubicin from the PC backbone was more
concentrated in the perinuclear region than in
the general cytosol.

Cytoplasm
The cytoplasm of cells treated with αvβ3DOX-PD PFOB-NPs demonstrated fluorescence signal at all time points with consistently
high signal noted in the perinuclear space
(Figure 4A, red arrows). This region coincides
with the location of Golgi/ER, which is
associated with enriched levels of cytosolic
phospholipase A2 (cPLA2) activity [42].
Comparisons within and outside the bright
perinuclear regions showed lower τamp (1.8 ns
± 0.2 ns, n=15 ROI) in the perinuclear regions
than the later (τamp = 2.9 ns ± 0.3 ns, n=15 ROI).
The lower τamp observed in bright perinuclear
region was due to greater contribution from a
faster lifetime component (1.1 ns, 82% ± 3%)
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the optical diffraction limit. The AF488-PD,
which contains fluorescent AF488 molecules
conjugated to the phospholipid at the Sn-2
position, preferentially intercalated into the
outer membrane leaflet of cells.

Super-resolution microscopy of cellular
binding and internalization of prodrug
molecules

Single-molecule super-resolution microscopy
(SRM) captures images of fluorescent
molecules with nanometer resolution beyond

Figure 5. Early-stage binding of AF488-PD on the membrane and internalization in 2F2B cells. (A) Bright-field and superresolution images of AF488-PD (red, after 5 min incubation) and cell membrane probe MC540 (green) on the membrane of
a 2F2B cell. The overlay images are focused at different heights above the coverslip. The arrows indicate the colocalized
active binding sites of AF488-PD and MC540 on the membrane. (B) Both transient binding and diffusion (trajectories on the
right part of the image) of single AF488-PD molecules were observed on the cell membrane after 5 min incubation.
Trajectories on the filopodia were not shown. Magnified views of the boxed regions shown in insets: (i) scatter plot of single
AF488-PD molecules (red) binding to filopodia, (ii, iii) representative trajectories of single AF488-PD molecule diffusing on
the cell membrane with the total length of 3.50 s and 1.65 s, respectively; color-coded for time. (C) Fluorescence images of
AF488-PD (red) after a 12-hour incubation at different heights above the coverslip, showing intracellular accumulation of
the prodrug. PAINT images of MC540 (green) indicate the contour of the cell membrane. CS, coverslip; MEM, membrane;
CY, cytoplasm; NU, nucleus.
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In 2F2B endothelial cells, AF488-PD (Figure
5A, red) was imaged within the cell membrane
after 5 min of incubation, co-localizing with
another membrane marker dye, MC540 (Figure
5A, green). As noted in the bright field images
shown in Figure 5A, SRM of AF488-PD and
MC540 both accumulated in the outer cell
membrane at different z heights (1, 2, 3 μm)
above the coverslip. These merged PAINT
images suggested that the PC prodrug
inherently incorporated into the cell membrane
with little spatial restriction between the base of
the cell on the coverslip and the apical surface
fully exposed to the bulk media. In addition to
the primary cell body surface membrane,
AF488-PD also incorporated into 2F2B cell
filopodia processes as noted in the magnified
image of the box (i) in Figure 5B. In
contradistinction, standard epifluorescence
microscopy imaging showed that the PErhodamine did not broadly intercalate into the
outer phospholipid cell membrane but was
primarily associated with the cell along the
coverslip region where cell adherent molecules
are highly expressed and engaged (Figure S6).
This observation was consistent with the report
of Partlow et al, which associated PErhodamine uptake with specific lipid-raft
membrane regions [4].
The diffusion of single molecules of AF488PD through the cytosol was imaged using
single-molecule
fluorescence
imaging
(Supplementary video S1). The trajectories

shown in Figure 5B illustrated the trackable
paths of single prodrug molecules prior to
photobleaching, diffusion beyond the focal
plane of the microscope, or enzymatic dye
liberation into the cytosol. Two representative
trajectories are presented in the magnified
images, box (ii) and (iii), in Figure 5B.
Individual freely-diffusing prodrug molecules
were also observed at the coverslip level of the
cell, which likely reflected the rapid mobility of
cell membrane phospholipid constituents [43].
With longer incubation times at 37 °C more
AF488-PD entered the membrane from the
media and internalized into the cell. Figure 5C
shows the fluorescence images of 2F2B cells
after incubation with AF488-PD for 12 h. At
this stage, AF488 fluorophores accumulated
broadly within the internal cell membranes
particularly in the perinuclear region,
corroborating the fluorescence microscopy
observation. Fluorescence images obtained at
different z heights (Figure 5C at 0.5, 2.5, 6.5 μm
above the coverslip) showed dye throughout the
cell with the intensity of the light signal
proportional to the proximity of AF488-PD to
the microscope’s focal plane, while the
autofluorescence background from 2F2B cells
was low (Figure S7). Diffuse red signal
associated with AF488-PD was noted beyond
the microscope’s depth of field. The rapid
motion of freely diffusing liberated AF488
molecules were not resolved in the cytoplasm
(Figure 5C).

Discussion
In vivo efficacy of Sn-2 PC prodrugs
incorporated into the surfactant of lipidencapsulated
nanoparticles
has
been
demonstrated previously [9-12]. These studies
showed that the Sn-2 PC PD motif inhibited
significant premature drug loss and drug
metabolism during circulation to the targeted
pathology. However, evidence corroborating
prodrug avoidance of internalization and
sequestration within the endosome/lysosome
pathway versus CFDD-mediated translocation
into intracellular membrane distribution with
subsequent enzymatic drug liberation was
lacking. In the present series of experiments,
PC prodrug delivery into cells and intracellular
trafficking was investigated using three
complementary optical imaging methods:
classic fluorescence microscopy, fluorescence
lifetime imaging microscopy, and singlemolecule super-resolution microscopy. The
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overarching result suggests that the PC
prodrugs act as mimics of phosphatidylcholine
with regard to cell membrane uptake,
membrane leaflet translocation, intracellular
distribution, and enzymatic metabolism in
normal and cancerous cell lines.
In prior research with rhodamine-PE as a lipid
drug surrogate in αvβ3-targeted lipidencapsulated NP, access into cells was confined
to lipid rafts and transfer of the fluorescent PE
from the outer to inner cell membrane leaflets
was dependent on ATP, consistent with the a
well-known amino-phospholipid flippase
transport protein mechanism. In ATP-starved
situations, such as hypoxic cancer cells,
targeted delivery of PE-based prodrugs could
be compromised. In contradistinction, PCprodrugs intercalated throughout the outer cell
membrane
leaflet,
including
filopodia
processes and translocated to the inner leaflet
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rapidly at 37 °C. ATP-suppressing cold
treatment (4 °C) partially inhibited the outer to
inner membrane leaflet translocation of PCprodrug, but substantial drug transferred into
the inner leaflet and then migrated throughout
the cytosolic membranes. These data suggest
that DOX-PD and other PC-PD will translocate
between membrane leaflets by ATP-dependent
and ATP-independent mechanisms and slowly
diffuse into cells in the absence of energy.
Moreover, spatially unrestricted cell entry
combined with ATP independent translocation
into the cell are both favorable for drug
delivery.
PC prodrugs broadly disseminated into
cytosolic membranes overtime, but a
significant intracellular trajectory was noted in
the lipid membranes of vesicles, likely
endosomes, trafficking toward the perinuclear
nuclear Golgi/ER region, a pathway welldocumented for native PC [26].
The
perinuclear Golgi/ER region has enriched
concentrations of cytoplasmic phospholipase
A2, a lipase involved in the degradation and
recycling of phosphatidylcholine [42, 44].
Enhanced local perinuclear enzymatic
liberation was demonstrated with doxorubicin
Sn-2 prodrug (DOX-PD) and fluorescence
lifetime microscopy. In perinuclear Golgi/ER
region, increased concentrations of free
doxorubicin were estimated. In other
cytoplasmic membrane regions with prevalent
DOX-PD retention, substantially lower
concentrations of released drug were estimated.
Fluorescence lifetime imaging further
demonstrated that the PC-released doxorubicin
entered the nucleus and bound to dsDNA
similar to native doxorubicin. In culture, free
doxorubicin entered cells rapidly and localized
to the nucleus with negligible cytoplasm
retention. By comparison, DOX-PD entered

the cell after NP targeting and a visually
significant portion of the drug rapidly bound
within the nucleus. However, unlike free DOX,
less drug was observed in the nucleus and a
significant proportion of the prodrug remained
within
the
cytoplasmic
membranes.
Nevertheless, the biopotency of the native and
prodrugs were at least equivalent with regard to
cell proliferation when measured by MTT assay
at 48 hours. If the drug cytotoxicity is directly
correlated to the compound bound to dsDNA,
then the residual prodrug within the
intracellular membrane may have constituted a
slower release depot with continued drug
liberated over the 48-hour experiment
increasing
nuclear
DOX
delivery.
Alternatively, the slower translocation of DOXPD to the nucleus with residual cytoplasm
retention
may
have
increased
the
antiproliferative contributions of other
pathways of doxorubicin toxicity, such as in the
mitochondria [45].
In the present study, definitive confirmation
of PC-PD migration to the Golgi, specifically,
was not established and tracking to the
endoplasmic reticulum or both organelles in the
perinuclear region could not be differentiated.
Additionally, the potential role of doxorubicin
exocytosis when delivered as the prodrug
versus free drug form was not studied.
Attention was placed on the binding of liberated
DOX to DNA over time, which evolved slowly
from the retained cytosol membrane depot.
Finally, the MTT assay was used to assess cell
apoptosis. Although careful washing of residual
doxorubicin prior to the addition of assay
reagents to the cell culture was performed, a
complementary
caspase
assay
might
additionally inform whether the treated cells
cycled into apoptosis versus the control.

Conclusion
Sn-2 lipase labile phospholipid prodrugs in combination with the contact-facilitated drug
delivery mechanism have been demonstrated for targeted nanoparticle therapy in vivo. In this report,
traditional fluorescence microscopy, fluorescence lifetime imaging, and single-molecule superresolution imaging techniques were used to elucidate the intracellular trafficking and metabolism details
of PC prodrugs for the first time. PC prodrugs incorporated broadly into the outer cell membrane leaflet
over the cell body and filopodia, and translocated to the inner membrane leaflet by ATP-dependent and
ATP-independent mechanisms. Nanoparticles were not sequestered into endosomal vesicles, but the PC
prodrugs delivered into the cells populated vesicle membranes that trafficked to the perinuclear
Golgi/ER region as well as distributed through the intracellular membranes in the cytosol. As an
example, doxorubicin-prodrug tracked to the Golgi/ER region where the highest level of liberated drug
was measured compared to the general cytosol. The released anthracycline displayed similar
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fluorescence lifetimes when bound to dsDNA as the native. In contradistinction to free doxorubicin,
which transferred directly to the nucleus after cell uptake, a significant portion of DOX-PD remained
within cytosolic membranes. Nevertheless, the biopotency of the native and prodrugs were at least
equivalent with regard to cell proliferation at 48 h, which suggests that the retained DOX-PD may have
constituted a prolonged release reservoir that enhanced effectiveness over two days. While the specific
fluorescence lifetimes measured in the present study have limited relationship with values for in vivo
imaging, this study provided the first evidence-based understanding of intracellular Sn-2 PC prodrug
fate.
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Video S1. Video clip showing the single-molecule fluorescence images of AF488-PD molecules on a
2F2B cell within the same field of view as in Figure 5B in the main text. The trajectory from 0.55 to
4.00 s indicates the diffusive path of a single AF488-PD molecule on the cell membrane (see also,
Figure 5B, inset (ii) in the main text).
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